Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Schering AG has initiated three phase II studies in Europe evaluating its investigational compound, ZK-EPO, for the treatment of several types of cancers such as non-small cell lung cancer, ovarian cancer and breast cancer.
Subscribe to our email newsletter
The clinical trials will assess ZK-EPO’s safety and efficacy in each of these cancer types. ZK-EPO is the only fully synthetic epothilone in clinical development, and is designed to improve efficacy and safety compared to the chemotherapies currently available.
In non-small cell lung cancer, a multi-center study is currently enrolling patients in Germany. The trial is designed to examine the efficacy and safety of ZK-EPO as second-line therapy in patients with advanced disease.
The ovarian cancer trial is a multi-center phase II study that is being conducted in the UK. The study is currently enrolling patients with recurrent ovarian cancer.
The breast cancer trial will enroll patients in 24 medical centers in a number of European countries. The first study centers have been initiated in France and Austria. The trial will investigate the efficacy of ZK-EPO in patients with metastatic breast cancer.
“The start of these clinical trials in three distinct solid tumor indications represents an important step in Schering’s development program, and we are excited by the opportunity to explore ZK-EPO in a variety of solid tumor indications. The phase I data leads us to believe ZK-EPO has potential to become an important new anticancer therapy to treat people with a variety of solid tumors,” said Carlo Montagner, head of oncology, Schering Group.